A broadly neutralizing human monoclonal antibody is effective against H7N9
- 17 August 2015
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (35) , 10890-10895
Abstract
Emerging strains of influenza represent a significant public health threat with potential pandemic consequences. Of particular concern are the recently emerged H7N9 strains which cause pneumonia with acute respiratory distress syndrome. Estimates are that nearly 80% of hospitalized patients with H7N9 have received intensive care unit support. VIS410, a human antibody, targets a unique conserved epitope on influenza A. We evaluated the efficacy of VIS410 for neutralization of group 2 influenza strains, including H3N2 and H7N9 strains in vitro and in vivo. VIS410, administered at 50 mg/kg, protected DBA mice infected with A/Anhui/2013 (H7N9), resulting in significant survival benefit upon single-dose (−24 h) or double-dose (−12 h, +48 h) administration (P < 0.001). A single dose of VIS410 at 50 mg/kg (−12 h) combined with oseltamivir at 50 mg/kg (−12 h, twice daily for 7 d) in C57BL/6 mice infected with A/Shanghai 2/2013 (H7N9) resulted in significant decreased lung viral load (P = 0.002) and decreased lung cytokine responses for nine of the 11 cytokines measured. Based on these results, we find that VIS410 may be effective either as monotherapy or combined with antivirals in treating H7N9 disease, as well as disease from other influenza strains. Significance Emerging influenza subtypes, such as the recently identified H7N9 strains, are of considerable public health concern. Although vaccines are an important countermeasure, influenza vaccines tend to be subtype- and strain-specific, such that they may not be widely available in the event of the human adaptation and spread of an unanticipated strain or subtype. Additionally, influenza strains have demonstrated the ability to develop resistance to existing antivirals, including oseltamivir. As such, there is a need for novel interventions that can treat and/or prevent serious influenza infection. We demonstrate that VIS410, a human mAb, neutralizes a wide range of influenza A viruses and effectively manages H7N9 infection.Keywords
This publication has 29 references indexed in Scilit:
- The Novel Human Influenza A(H7N9) Virus Is Naturally Adapted to Efficient Growth in Human Lung TissuemBio, 2013
- Pathogenicity of the Novel A/H7N9 Influenza Virus in MicemBio, 2013
- A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope GlycoproteinPLOS Computational Biology, 2013
- Networks link antigenic and receptor-binding sites of influenza hemagglutinin: Mechanistic insight into fitter strain propagationScientific Reports, 2011
- Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational DesignScience, 2011
- The DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B VirusesJournal of Virology, 2011
- A Highly Conserved Neutralizing Epitope on Group 2 Influenza A VirusesScience, 2011
- Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled TrialPLOS Medicine, 2010
- Cross-Reactive Neutralizing Antibodies Directed against Pandemic H1N1 2009 Virus Are Protective in a Highly Sensitive DBA/2 Mouse Influenza ModelJournal of Virology, 2010
- Host Genetic Variation Affects Resistance to Infection with a Highly Pathogenic H5N1 Influenza A Virus in MiceJournal of Virology, 2009